Abstract SOX2 positive pituitary stem cells (PSCs) are specified embryonically and persist throughout life, giving rise to all pituitary endocrine lineages. We have previously shown the activation of the STK/LATS/YAP/TAZ signalling cascade in the developing and postnatal mammalian pituitary. Here, we investigate the function of this pathway during pituitary development and in the regulation of the SOX2 cell compartment. Through loss-and gain-offunction genetic approaches, we reveal that restricting YAP/TAZ activation during development is essential for normal organ size and specification from SOX2+ PSCs. Postnatal deletion of LATS kinases and subsequent upregulation of YAP/TAZ leads to uncontrolled clonal expansion of the SOX2+ PSCs and disruption of their differentiation, causing the formation of non-secreting, aggressive pituitary tumours. In contrast, sustained expression of YAP alone results in expansion of SOX2+ PSCs capable of differentiation and devoid of tumourigenic potential. Our findings identify the LATS/YAP/TAZ signalling cascade as an essential component of PSC regulation in normal pituitary physiology and tumourigenesis.
Introduction
SOX2 is a crucial transcription factor involved in the specification and maintenance of multiple stem cell populations in mammals. Pituitary stem cells express SOX2 and contribute to the generation of new endocrine cells during embryonic development and throughout postnatal life (Andoniadou et al., 2013; Rizzoti et al., 2013) . The pituitary gland is composed of three parts, the anterior, intermediate and posterior lobes (AL, IL and PL, respectively) . The AL and IL contain hormone-secreting cells, which are derived from an evagination of the oral ectoderm expressing SOX2, termed Rathke's pouch (RP). SOX2+ cells, both in the embryonic and adult pituitary, can differentiate into three endocrine cell lineages, which are marked by transcription factors PIT1 (POU1F1) (Li et al., 1990) , TPIT (TBX19) (Pulichino et al., 2003) and SF1 (NR5A1) (Ingraham et al., 1994) , and differentiate into hormone-secreting cells (somatotrophs, lactotrophs, thyrotrophs, corticotrophs, melanotrophs and gonadotrophs, which express growth hormone, prolactin, thyrotropin, adrenocorticotropin, melanotropin and gonadotropin, respectively). SOX2+ PSCs are highly proliferative during the first 2-3 weeks of life, in concordance with major organ growth, after which they reach a steady low proliferative capacity that contributes to maintain normal homeostasis and physiological adaptation of the pituitary gland (Levy, 2002; Nolan et al., 1998) .
Contrary to other organs, where somatic stem cells are shown to be able to become transformed into cancer stem cells, the roles of SOX2+ PSCs in tumourigenesis remain poorly understood, possibly due to the patchy knowledge of the pathways regulating SOX2+ PSC fate and proliferation. Pituitary tumours are common in the population, representing 10-15% of all intracranial neoplasms (Bronstein et al., 2011; Daly et al., 2006) . Adenomas are the most common adult pituitary tumours, classified into functioning, when they secrete one or more of the pituitary hormones, or non-functioning if they do not secrete hormones. In children, adamantinomatous craniopharyngioma (ACP) is the most common pituitary tumour. Targeting oncogenic beta-catenin in SOX2+ PSCs in the mouse generates clusters of senescent SOX2+ cells that induce tumours resembling ACP in a paracrine manner, that is the tumours do not derive from the targeted SOX2+ PSCs (Andoniadou et al., 2013; Gonzalez-Meljem et al., 2017) . Up to 15% of adenomas and 50% of ACP display aggressive behaviour with invasion of nearby structures including the hypothalamus and visual tracts, associated with significant morbidity and mortality (Lasolle et al., 2017) . Pituitary carcinomas exhibiting metastasis are rare but can develop from benign tumours (Veldhuis, 2013; Pernicone et al., 1997; Heaney, 2014) . Whether SOX2+ cells can cell autonomously contribute to pituitary neoplasia has not been hitherto demonstrated.
The Hippo pathway controls stem cell proliferation and tumourigenesis in several organs such as in the liver (Zhou et al., 2009; Lu et al., 2018) , intestines and lung (Lin et al., 2015; Nantie et al., 2018) . In the core phosphorylation cascade, STK3/4 kinases phosphorylate and activate LATS1/2 serine/threonine-protein kinases, which in turn phosphorylate co-activators Yesassociated protein (YAP1, a.k.a. YAP) and WW domain-containing transcription regulator protein 1 eLife digest The pituitary is a gland inside the head that releases hormones that control major processes in the body including growth, fertility and stress. Diseases of the pituitary gland can prevent the body from producing the appropriate amounts of hormones, and also include tumours.
A population of stem cells in the pituitary known as SOX2 cells divide to make the specialist cells that produce the hormones. This population forms as the pituitary develops in the embryo and continues to contribute new hormone-producing cells throughout life. Signals from inside and outside the gland control how the pituitary develops and maintain the correct balance of different types of cells in the gland in adults.
In 2016, Lodge et al. reported that a cascade of signals known as the Hippo pathway is active in mouse and human pituitary glands, but its role remained unclear. Here, Lodge et al. use genetic approaches to study this signalling pathway in the pituitary of mice.
The results of the experiments show that the Hippo pathway is essential for the pituitary gland to develop normally in mouse embryos. Furthermore, in adult mice the Hippo pathway is required to maintain the population of SOX2 cells in the pituitary and to regulate their cell numbers. Increasing the level of Hippo signalling in mouse embryos and adult mice led to an expansion of SOX2 stem cells that could generate new specialist cell types, but a further increase generated aggressive tumours that originated from the uncontrolled growth of SOX2 cells.
These findings are the first step to understanding how the Hippo pathway works in the pituitary, which may eventually lead to new treatments for tumours and other diseases that affect this gland. The next step towards such treatments will be to carry out further experiments that use drugs to control this pathway and alter the fate of pituitary cells in mice and other animals.
(WWTR1, a.k.a. TAZ) that are subsequently inactivated through degradation and cytoplasmic retention (Meng et al., 2016) . Active YAP/TAZ associate with TEAD transcription factors, promoting the transcription of target genes such as Cyr61 and Ctgf (Zhao et al., 2008; Zhang et al., 2009; Zhou et al., 2016) . YAP/TAZ have been shown to promote proliferation and the stem cell state in several organs, and can also lead to transformation and tumour initiation when overexpressed (Camargo et al., 2007; Schlegelmilch et al., 2011; Dong et al., 2007) . The involvement of YAP/ TAZ in the function of tissue-specific SOX2+ stem cells during development and homeostasis has not been shown. We previously reported strong nuclear localisation of YAP and TAZ exclusively in SOX2+ stem cells of developing Rathke's pouch and the postnatal anterior pituitary of mice and humans, and enhanced expression in human pituitary tumours composed of uncommitted cells, including ACPs and null-cell adenomas (Lodge et al., 2016; Xekouki et al., 2019) , which do not express any of the lineage transcription factors PIT1, TPIT or SF1. In these populations we detected phosphorylation of YAP at serine 127 (S127) indicating LATS kinase activity. Together these point to a possible function for LATS/YAP/TAZ in normal pituitary stem cells and during tumourigenesis. Here, we have combined genetic and molecular approaches to reveal that deregulation of the pathway can promote and maintain the SOX2+ PSC fate under physiological conditions and that major disruption of this axis transforms SOX2+ PSCs into cancer-initiating cells giving rise to aggressive tumours.
Results

Sustained conditional expression of YAP during development promotes SOX2+ PSC fate
To determine if YAP and TAZ function during embryonic development of the pituitary, we used genetic approaches to perform gain-and loss-of-function experiments. We first expressed a constitutive active form of YAP(S127A) using the Hesx1-Cre driver, which drives Cre expression in Rathke's pouch (RP) and the hypothalamic primordium from 9.5dpc, regulated by administration of doxycycline through the reverse tetracycline-dependent transactivator (rtTA) system (R26 rtTA/+ ; see Materials and methods for details, Scheme Figure 1A ). Analyses were restricted to embryonic time points. As expected, we confirmed accumulation of total YAP protein but not of TAZ or pYAP(S127), throughout the developing pituitary and hypothalamus of Hesx1 Cre/+ ;R26 rtTA/+ ;Col1a1 tetO-Yap/+ (hereafter YAP-TetO) embryos at 15.5dpc, but not of Cre-negative controls ( Figure 1B , Figure 1 figure supplement 1A). Likewise, the YAP downstream target Cyr61 ( Figure 1B ) was also upregulated. Morphologically, YAP-TetO mutants displayed a dysplastic anterior pituitary, which was more medially compacted and lacked a central lumen, making it difficult to distinguish between the developing anterior and intermediate lobes ( Figure 1C ). Immunofluorescence staining against SOX2 at 15.5dpc demonstrated loss of SOX2 in the most lateral regions of control pituitaries (arrows in Figure 1C ), where cells are undergoing commitment; yet mutant pituitaries had abundant SOX2 positive cells in the most lateral regions (arrowheads in Figure 1C ). Immunostaining for LHX3, which is expressed in the developing anterior pituitary (Sheng et al., 1996) , was used to demarcate AL and IL tissue. Staining using antibodies against lineage markers PIT1, TPIT and SF1 revealed a concomitant reduction in committed cell lineages throughout the gland ( Figure 1D ; PIT1 0.35% in mutants compared with 30.21% in controls (Student's t-test p<0.0001, n = 3 for each genotype), TPIT 1.03% in mutants compared with 9.81% in controls (Student's t-test p=0.0012, n = 3 for each genotype), SF1 0.34% in mutants compared with 4.14% in controls (Student's t-test p=0.0021, n = 3 for each genotype)). We therefore conclude that sustained activation of YAP prevents lineage commitment and is sufficient to maintain the progenitor state during embryonic development. We did not obtain any live Hesx1 Cre/+ ;R26 rtTA/+ ;Col1a1 tetO-Yap/+ pups at birth when treated with doxycycline from 5.5dpc (n = 5 litters). To bypass the embryonic lethality of these early inductions, we commenced doxycycline treatment from 9.5dpc, the onset of RP formation ( Figure 1 -figure supplement 1B).
Hesx1
Cre/+ ;R26 rtTA/+ ;Col1a1 tetO-Yap/+ pups were viable and were maintained on doxycycline until P24, at which point the experimental end point was reached due to excessive weight loss and animals had to be culled following UK Home Office Regulations. Histological analyses of pituitaries revealed multiple anterior lobe cysts per gland, localising predominantly in the ventral AL (n = 4) fl mutants compared to the ample capillaries seen in the control ( Figure 2C ), which may account for the necrosis. This could be due to a direct inhibition of vascularisation or a consequence of the rapid growth of this embryonic tumour. We frequently observed ectopic residual pituitary tissue at more caudal levels, reaching the oral epithelium and likely interfering with appropriate fusion of the sphenoid, similar to other phenotypes involving pituitary enlargement (arrows Figure 2C ) (Andoniadou et al., 2012; Sajedi et al., 2008; Gaston-Massuet et al., 2008) . Immunofluorescence to detect active (non-phosphorylated) YAP revealed abundant staining throughout the pituitary at 15.5dpc, compared to the control where active YAP localises in the SOX2 epithelium ( Figure 2C ). Immunofluorescence using specific antibodies against lineage commitment markers PIT1, TPIT and SF1 at 15.5dpc revealed very few cells expressing PIT1, TPIT and SF1 in the double mutant ( Figure 2D ; PIT1 9.14% in mutants compared with 51.4% in controls (Student's t-test p<0.0001); TPIT 4.0% in mutants compared with 11.4% in controls (Student's t-test p<0.007); SF1 2.1% in mutants compared with 6.5% in controls (Student's t-test p>0.05) n = 3 mutants and five controls), suggesting failure to commit into the three lineages. These data suggest that the LATS/YAP/TAZ axis is required for normal embryonic development of the anterior pituitary and that LATS1/2 kinases control proliferation of SOX2+ progenitors and their progression into the three committed lineages.
Loss of LATS kinases results in carcinoma-like murine tumours
Postnatal analysis of Hesx1 Cre/+ ;Lats1 fl/fl pituitaries revealed that by P56, despite developing normally during the embryonic period, all glands examined exhibited lesions of abnormal morphology consisting of overgrowths, densely packed nuclei and loss of normal acinar architecture (n = 15). To minimise the likely redundancy by LATS2 seen at embryonic stages, we generated Lats1 mutants additionally haploinsufficient for Lats2 ( Histological examination of Hesx1 Cre/+ ;Lats1 fl/fl ;Lats2 fl/+ pituitaries confirmed the abnormal lesions were tumours, characterised by frequent mitoses, focal necrosis, and a focal squamous differentiation, as well as the occasional presence of cysts ( Figure 3A) . These lesions were identical to those in Hesx1 Cre/+ ;Lats1 fl/fl pituitaries (not shown). These tumours accumulated YAP/TAZ and upregulated expression of targets Cyr61 and Ctgf ( Figure 3B ), confirming the validity of the genetic manipulation ( Figure 3B ). Tumours were also frequently observed in the anterior and intermediate lobe (Figure 3-figure supplement 1C) . Analysis of proliferation by Ki-67 immunostaining revealed an elevated mitotic index of 7-28% in tumours (mean 15.46, SEM ±2.74), compared to 2.97% (SEM ±1.2) mean in control pituitaries not carrying the Lats1 deletion ( Figure 3C ). In keeping with the morphological evidence of epithelial differentiation ( Figure 3A) , the tumours were positive for cytokeratins using AE1/AE3 (multiple keratin cocktail) (Figure 3-figure supplement 1E). Furthermore, the tumours showed focal morphological evidence of squamous differentiation and showed positive nuclear p63 staining, frequently expressed in squamous carcinomas Figure 3D ). Consistent with a tumourigenic phenotype, and role for LATS1 genomic stabilisation (Pefani et al., 2014) , staining for gamma-H2A.X detected elevated DNA damage in cells of the mutant pituitaries compared with controls ( Figure 3-figure supplement 1D ). The absence of adenoma or oncocytoma markers together with the histological appearance, observation of focal necrosis and a high mitotic index support the features of squamous carcinoma.
SOX2+ cells are the cell of origin of the tumours
Tumour regions were mostly composed of SOX2 positive cells, a sub-population of which also expressed SOX9 ( Figure 3E , Figure 3 -figure supplement 1A; 85-97% of cells, 7 tumours across four pituitaries). Close examination of the marginal zone epithelium, a major SOX2+ stem cell niche of the pituitary, revealed a frequent 'ruffling' resembling crypts, likely generated through over-proliferation of the epithelial stem cell compartment ( Figure 3F ). To determine if the cell of origin of the tumourigenic lesions is a deregulated SOX2+ stem cell, we carried our specific deletion of LATS1/2 in postnatal SOX2+ cells using the tamoxifen-inducible Sox2-CreERT2 driver, combined with conditional expression of membrane-GFP in targeted cells (Sox2 CreERT2/+ ;Lats1 fl/fl ;Lats2 fl/+ ;R26 mTmG/+ ).
Tamoxifen induction at P5 or P21, led to abnormal lesions in the anterior pituitary within three months in all cases. We focused our analyses on inductions performed at P5, from which time point all animals developed lesions by P35 ( Figure 4A YAP expression is sufficient to activate pituitary stem cells
Conditional deletion of LATS1/2 kinases in the pituitary has revealed how these promote an expansion of SOX2+ stem cells in the embryonic and postnatal gland at the expense of differentiation. To establish if this effect was mediated through YAP alone, we used the tetracycline-controlled conditional YAP-TetO system to promote YAP (S127A) protein levels in postnatal pituitaries of Hesx1 Cre/+ ; R26 rtTA/+ ;Col1a1 tetO-Yap/+ mice. We treated YAP-TetO animals with doxycycline from P21 to P105 Immunofluorescence against SOX2 demonstrated a significant increase in the number of SOX2 + cells as a proportion of the anterior pituitary (Figure 5B,F; 18.0% compared to 12.1% in controls, p=0.0014), a finding recapitulated by SOX9 that marks a subset of the SOX2 population ( Figure 5B ). This increase in the percentage of SOX2+ cells was maintained at all stages analysed ( Figure 5F ) and did not affect the overall morphology of the pituitary. At P42 we observed a significant increase in proliferation among the SOX2+ pituitary stem cells from 3% in controls to 15% in mutants (p=0.027). SOX2+ cells make up 10% of all cycling cells (Ki-67%) in normal pituitaries, however in mutants this increased to 25%, suggesting a preferential expansion of the SOX2+ population, rather than an overall increase in proliferation ( Figure 5C ). No additional marked differences were observed in samples analysed at P63 (6 weeks of treatment, n = 3), however longer treatment (P21 to P105) resulted in sporadic regions of expanded SOX2+ cells ( Figure 5-figure supplement 1C) . These regions did not express the commitment marker PIT1 and were identifiable by haematoxylin/ eosin staining. In contrast to tumour lesions generated following loss of LATS kinases, these were not proliferative, were positive for pYAP and did not accumulate high levels of YAP/TAZ (n = 6 lesions). Together these results suggest that the sustained expression of constitutive active YAP can activate the proliferation of SOX2 stem cells, but in contrast to deletion of LATS1, this alone is not oncogenic.
To establish if the expansion of pituitary stem cells following forced expression of YAP is reversible, we administered doxycycline to YAP-TetO animals for three weeks (P21 to P42) by which point there is a robust response, followed by doxycycline withdrawal for three weeks (until P63) to allow sufficient time for YAP levels to return to normal (scheme Figure 5D ). Immunofluorescence against total YAP protein confirmed restoration of the normal YAP expression pattern and levels after recovery ( Figure 5E ), and mRNA in situ hybridisation detected a reduction in expression of YAP/TAZ targets Cyr61 and Ctgf ( Figure 5-figure supplement 1D) . Following recovery from high levels of YAP, the number of SOX2+ cells reduced to comparable levels as in controls (around 10% of the total anterior pituitary) ( Figure 5E,F) . This suggests that the effects of YAP overexpression on the stem cell population are transient following three weeks of treatment ( Figure 5F ). Finally, to determine if SOX2+ cells could differentiate into hormone-producing cells after the reduction in YAP levels, we expressed constitutive active YAP only in SOX2+ cells while lineage tracing this population (Sox2 CreERT2/+ ;R26 rtTA/mTmG ;Col1a1 tetO-Yap/+ ). We induced SOX2+ cells by lowdose tamoxifen administration at P21 and treated with doxycycline for three weeks, followed by doxycycline withdrawal for a further three weeks ( Figure 5G ). Larger clones of SOX2 derivatives were observed at P63 in Sox2 CreERT2/+ ;R26 rtTA/mTmG ;Col1a1 tetO-Yap/+ animals compared to controls, and these still contained SOX2+ cells ( Figure 5H ). Following withdrawal, we were able to detect GFP+ derivatives of SOX2+ cells, which had differentiated into the three lineages (PIT1, SF1 and ACTH, marking corticotrophs of the TPIT lineage) ( Figure 5I ). Taken together, these findings confirm that sustained expression of YAP is sufficient to maintain the SOX2+ state and promote activation of normal SOX2+ pituitary stem cells in vivo, driving expansion of this population.
Discussion
Here we establish that regulation of LATS/YAP/TAZ signalling is essential during anterior pituitary development and can influence the activity of the stem/progenitor cell pool. LATS kinases, mediated by YAP and TAZ, are responsible for controlling organ growth, promoting an undifferentiated state and repressing lineage commitment. Loss of both Lats1 and Lats2, encoding potent tumour suppressors, leads to dramatic tissue overgrowth during gestation, revealing a function for these enzymes in restricting growth during pituitary development. The involvement of YAP/TAZ and dysfunction of the kinase cascade is emerging in multiple paediatric cancers, which are often developmental disorders (Ahmed et al., 2017) . Loss of LATS1 heterozygosity has been reported in a range of human tumours (Lee et al., 1990; Chen et al., 2005; Theile et al., 1996; Mazurenko et al., 1999) leading to an increase in YAP/TAZ protein levels. Previous global deletion of Lats1 in mice resulted in a variety of soft tissue sarcomas and stromal cell tumours (St John et al., 1999) . The anterior lobe of these animals appeared hyperplastic with poor endocrine cell differentiation leading to combined hormone deficiencies, but the presence of tumours was not noted. We report that loss of Lats1 alone is sufficient to drive anterior and intermediate lobe tumour formation. This phenotype is accelerated following additional deletion of one copy of Lats2. Phenotypically identical tumour lesions were generated when the genetic deletions were carried out embryonically in RP, or at postnatal stages. Interestingly, tissue-specific loss of Stk3 and Stk4, which regulate LATS activation in other tissues (Hu et al., 2017) , did not lead to any pituitary defects despite reduction in STK3/4 levels. These data suggest that perhaps the residual activity of STK3/4 is sufficient for LATS1/2 activation. Alternatively, regulation of LATS1/2 by kinases other than STK3/4 is possible in the pituitary, meaning deletion of Stk3/4 alone is insufficient to result in significant LATS function impairment. Similar situations have been reported in other organs where LATS are functioning (Hu et al., 2017) . The resulting non-secreting tumours in our mouse models are composed predominantly of SOX2+ stem cells and display signs of squamous differentiation. Rare cases of squamous cell carcinoma have been reported as primary pituitary tumours (Saeger et al., 2007) , but more frequently, arising within cysts that are normally non-neoplastic epithelial malformations (Lewis et al., 1983; O'Neill et al., 2016) . In the embryonic YAP-TetO model, where constitutive active YAP (S127A) was expressed during pituitary development, cysts phenocopying Rathke's cleft cyst, develop by postnatal stages. Target elevation is not as high in YAP-TetO pituitaries, as following the deletion of LATS1/2, indicating that signalling levels are likely to be critical for progression between these phenotypes.
Although human pituitary carcinomas are only diagnosed as such after metastasis, the tumours generated in our LATS1/2 mouse models fit their histopathological profile. Genetic lineage tracing identified SOX2+ cells as the cell of origin of the tumours; this observation could have ramifications regarding involvement of the LATS/YAP/TAZ pathway in the establishment or progression of human pituitary tumours composed of uncommitted cells. In cancer stem cells of osteosarcoma and glioblastoma, SOX2 antagonises upstream Hippo activators, leading to enhanced YAP function (Basu-Roy et al., 2015) . We recently reported enhanced expression of YAP/TAZ in a range of non-functioning human pituitary tumours, compared to functioning adenomas, and that Lats1 knock-down in GH3 pituitary mammosomatotropinoma cells results in repression of the Gh and Prl promoters (Xekouki et al., 2019) . Therefore, YAP/TAZ, perhaps in a positive feedback loop with SOX2, are likely to function both to promote the maintenance of an active pituitary stem cell state as well as to inhibit differentiation.
By dissecting the downstream requirement for YAP in pituitary regulation by the LATS/YAP/TAZ axis, we found that expression of constitutively active YAP (S127A) is sufficient to push SOX2+ pituiitary stem cells into an activated state, leading to expansion of the stem cell cohort (see Model , Figure 6) . YAP has previously been indicated to promote the stem cell state in other tissues, for example pancreas, neurons and mammary glands (Panciera et al., 2016) . However, this does not fully recapitulate the LATS deletion phenotypes, as it did not lead to the formation of tumours during the time course of YAP activation (12 weeks). Interestingly, since the levels of target activation are significantly greater in Lats1/2 deletions that in YAP-TetO activation, initiation of tumourigenesis may be associated with levels of signalling rising above a threshold. However, the temporal control of expressing the mutation is critical, as seen in other tumour models (Han et al., 2016) . Instead, the findings identify an isolated role for YAP in promoting the expansion of the SOX2 + stem cell pool and restoring their proliferative potential to levels akin to the most active state during postnatal pituitary growth. Activity of YAP/TAZ is reduced in dense tissues, resulting in a decrease in stemness. One mechanism through which this is achieved is by crosstalk with other signalling pathways regulating stem cell fate (Papaspyropoulos et al., 2018; Heallen et al., 2011) . For example, a decrease in YAP/TAZ activity removes inhibition on Notch signalling, resulting in higher levels of differentiation and a drop in stem cell potential (Totaro et al., 2017) . In the pituitary, Notch plays a role in the maintenance of the SOX2 stem cell compartment and is involved in regulating differentiation (Zhu et al., 2015; Nantie et al., 2014; Cheung et al., 2013; Batchuluun et al., 2017) . The downstream mechanisms of YAP action on SOX2+ pituitary stem cells, as well as the likely crosstalk with other signalling pathways remain to be explored.
In summary, our findings highlight roles for LATS/YAP/TAZ in the regulation of pituitary stem cells, where fine-tuning of their expression can make the difference between physiological stem cell re-activation and tumourigenesis, of relevance to other organs. We reveal this axis is involved in the control of cell fate commitment, regulation of regenerative potential and promotion of tumourigenesis. These findings can aid in the design of treatments against pituitary tumours and in regenerative medicine approaches targeting the regulation of endogenous stem cells. Tamoxifen (Sigma, T5648) was administered to experimental mice by intraperitoneal injection at a single dose of 0.15 mg/g body weight, or two equal doses on sequential days, depending on the experiment. Mice for growth studies were weighed every week. For embryonic studies, timed matings were set up where noon of the day of vaginal plug was designated as 0.5dpc.
Materials and methods
For Figure 1A ), doxycycline (Alfa Aesar, J60579) was administered to pregnant dams in the drinking water at 2 mg/ml, supplemented with 10% sucrose. For postnatal analyses animals were treated with doxycycline or vehicle (DMSO) as described, from the ages specified for individual experiments on the Hesx1 Cre/+ driver, or directly following tamoxifen administration for animals on the Sox2
CreERT2/+ driver. Both male and female mice and embryos where included in the studies.
Tissue preparation
Embryos and adult pituitaries were fixed in 10% neutral buffered formalin (Sigma) overnight at room temperature. The next day, tissue was washed then dehydrated through graded ethanol series and paraffin-embedded. Embryos up to 13.5dpc were sectioned sagittal and all older embryo and postnatal samples were sectioned frontal, at a thickness of 7 mm for immunofluorescence staining, or 4 mm for RNAscope mRNA in situ hybridisation.
RNAscope mRNA in situ hybridisation
Sections were selected for the appropriate axial level, to include Rathke's pouch or pituitary, as described previously (Lodge et al., 2016) . The RNAscope 2.5 HD Reagent Kit-RED assay (Advanced Cell Diagnostics) was used with specific probes: Ctgf, Cyr61, Lats2 (all ACDBio).
H and E staining
Sections were dewaxed in histoclear and rehydrated through graded ethanol series from 100% to 25% ethanol, then washed in distilled H 2 O. Sections were stained with Haematoxylin QS (Vector #H3404) for 1 min, and then washed in water. Slides were then stained in eosin in 70% ethanol for 2 min and washed in water. Slides were dried and coverslips were mounted with VectaMount permanent mounting medium (Vector Laboratories H5000).
Immunofluorescence and immunohistochemistry
Slides were deparaffinised in histoclear and rehydrated through a descending graded ethanol series. Antigen retrieval was performed in citrate retrieval buffer pH6.0, using a Decloaking Chamber NXGEN (Menarini Diagnostics) at 110˚C for 3mins. Tyramide Signal Amplification (TSA) was used for staining using antibodies against YAP (1:1000, Cell Signaling #4912S), pYAP (1:1000, Cell Signaling #4911S), TAZ (1:1000, Atlas Antibodies #HPA007415) and SOX2 (1:2000, Abcam ab97959) with EMCN (1:1000, Abcam ab106100) staining as follows: sections were blocked in TNB (0.1M Tris-HCl, pH7.5, 0.15M NaCl, 0.5% Blocking Reagent (Perkin Elmer FP1020)) for 1 hr at room temperature, followed by incubation with primary antibody at 4˚C overnight, made up in TNB. Slides were washed three times in TNT (0.1MTris-HCl pH7.5, 0.15M NaCl, 0.05% Tween-20) then incubated with secondary antibodies (biotinylated anti-rabbit (1:350 Abcam ab6720) and anti-Rat Alexa Fluor 555 (1:300, Life Technologies A21434) for 1 hr at room temperature and Hoechst (1:10000, Life Technologies H3570). Slides were washed again then incubated in ABC reagent (ABC kit, Vector Laboratories PK-6100) for 30 mins, followed by incubation with TSA conjugated fluorophore (Perkin Elmer NEL753001KT) for ten minutes. Slides were washed and mounted with VectaMount (Vector Laboratories H1000). For regular immunofluorescence, sections were blocked in blocking buffer (0.15% glycine, 2 mg/ ml BSA, 0.1% Triton-X in PBS), with 10% sheep serum (donkey serum for goat SOX2 antibody) for 1 hr at room temperature, followed by incubation with primary antibody at 4˚C overnight, made up in blocking buffer with 1% serum. Primary antibodies used were against SOX2 (1:250, Immune Systems Ltd GT15098), active YAP (1:300, Abcam ab205270), GFP (1:300, Abcam ab13970), Ki-67 (1:300, Abcam ab16667), SOX9 (1:300, Abcam ab185230), PIT1 (1:1000, Gift from S. Rhodes, Indiana University), TPIT (1:1000, Gift from J. Drouin, Montreal), SF1 (1:200, Life Technologies N1665), Gamma H2A.X (1:1000, Abcam ab2893), Vimentin (1:300, Cell Signaling #5741), Caspase (1:300, Cell Signaling #9661S). Slides were washed in PBST then incubated with secondary antibodies for 1 hr at room temperature. Appropriate secondary antibodies were incubated in blocking buffer for 1 hr at room temperature (biotinylated anti-rabbit (1:350, Abcam ab6720), biotinylated anti-mouse (1:350, Abcam ab6788), anti-chicken 488 (1:300, Life Technologies A11039), anti-goat 488 (1:300, Abcam ab150133). Slides were washed again using PBST and incubated with fluorophore-conjugated Streptavidin (1:500, Life Technologies S21381 or S11223) for 1 hr at room temperature, together with Hoechst (1:10000, Life Technologies H3570). Slides were washed in PBST and mounted with VectaMount (Vector Laboratories, H1000).
Quantifications and statistics
Cell counts were performed manually using Fiji cell counter plug-in; 5-10 fields were counted per sample, totalling over 1500 nuclei, across 3-7 pituitaries. Statistical analyses and graphs were generated in GraphPad Prism (GraphPad Software) and the following tests were performed to determine significance: Student's t-tests between controls and mutants for Figures 1D and 2D, Figure 2 Figure 3C (n = 3 controls, seven mutants); two-way ANOVA with Sidak's multiple-comparison test for Figure 5F (n = 4-5 of each genotype). For quantification of target expression by RNAscope mRNA in situ hybridisation ( Figure 5-figure supplement 1) , the area of positive staining (red fluorescence) from 4 mm sections was determined from images using thresholding in Fiji, and quantified as a percentage of total pituitary area in the same image. For statistical testing, one-way ANOVAs with Tukey's multiple comparisons were performed (n = 4 mutants per genotype). Error bars in graphs show ±standard error of the mean, unless otherwise indicated. Quantification of STK3/4 by western blot was carried out on two control (Stk3 Data availability According to UK research councils' Common Principles on Data Policy, all data generated or analysed during this study are included in the manuscript and supporting files.
